Roche Holding AG on Monday said new data showed cancer drug MabThera significantly extended survival and cured more patients with aggressive lymphoma than chemotherapy alone.
The Swiss drugmaker said a late-stage study of patients who used MabThera revealed that 53 percent were still alive after seven years compared with 36 percent for those who used chemotherapy alone.
Non-Hodgkin's lymphoma affects 1 million people worldwide. It is estimated that 360,000 people die each year from the disease.
No comments:
Post a Comment